Ingle JN - Search Results

1

The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.

Gingery A, Subramaniam M, Pitel KS, Reese JM, Cicek M, Lindenmaier LB, Ingle JN, Goetz MP, Turner RT, Iwaniec UT, Spelsberg TC, Hawse JR. Gingery A, et al. Among authors: ingle jn. PLoS One. 2014 May 22;9(5):e98219. doi: 10.1371/journal.pone.0098219. eCollection 2014. PLoS One. 2014. PMID: 24853369 Free PMC article.

2

Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.

Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova NSh, Mikhailov SN, Ingle JN, Spelsberg TC. Reinholz GG, et al. Among authors: ingle jn. Breast Cancer Res Treat. 2002 Feb;71(3):257-68. doi: 10.1023/a:1014418017382. Breast Cancer Res Treat. 2002. PMID: 12002344

3

Estrogen as therapy for breast cancer.

Ingle JN. Ingle JN. Breast Cancer Res. 2002;4(4):133-6. doi: 10.1186/bcr436. Epub 2002 May 15. Breast Cancer Res. 2002. PMID: 12100736 Free PMC article.

4

Sequencing of hormonal therapy in breast cancer.

Ingle JN. Ingle JN. Breast J. 2002 Nov-Dec;8(6):332-7. doi: 10.1046/j.1524-4741.2002.08602.x. Breast J. 2002. PMID: 12390355 Review.

5

Adjuvant endocrine therapy in postmenopausal breast cancer.

Ingle JN. Ingle JN. Clin Cancer Res. 2003 Jan;9(1 Pt 2):480S-5S. Clin Cancer Res. 2003. PMID: 12538504 Review.

6

Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.

Ingle JN. Ingle JN. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):362S-7S. doi: 10.1158/1078-0432.ccr-031200. Clin Cancer Res. 2004. PMID: 14734492

7

Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue.

Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, Roche PC, Spelsberg TC. Reinholz MM, et al. Among authors: ingle jn. Breast Cancer Res Treat. 2004 Jul;86(1):75-88. doi: 10.1023/B:BREA.0000032926.74216.7d. Breast Cancer Res Treat. 2004. PMID: 15218362

8

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM. Jelovac D, et al. Among authors: ingle jn. Clin Cancer Res. 2004 Nov 1;10(21):7375-81. doi: 10.1158/1078-0432.CCR-04-0565. Clin Cancer Res. 2004. PMID: 15534114

9

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Goetz MP, et al. Among authors: ingle jn. J Clin Oncol. 2005 Dec 20;23(36):9312-8. doi: 10.1200/JCO.2005.03.3266. J Clin Oncol. 2005. PMID: 16361630

10

Adjuvant endocrine therapy for postmenopausal women with early breast cancer.

Ingle JN. Ingle JN. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1031s-1036s. doi: 10.1158/1078-0432.CCR-05-2122. Clin Cancer Res. 2006. PMID: 16467121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

422 results

Search Page